-
Br J Cancer: Computer fault scanning (CT) has no advantage over chest XR in the initial assessment of pregnancy nourishing cell tumor formation
Time of Update: 2021-01-01
Compared to the patient's prognosis, the occurrence of SACR, the normal time of TNhCG (normal fluffy membrane gonadotrophic hormone) and primary chemotherapy resistance (PCR), CT-related chest scores were assessed as the main factors affecting treatment decision-making.
-
Cell Death Differ: Single-cell imaging studies have shown that BCL(X) L and BCL2 increase the metabolic adaptability of breast cancer cells
Time of Update: 2021-01-01
, however, there is very little research on the effects of BCL2 and BCL(X) L on mitochondrial bioenear energy and their relationship to MOMP processes at the single-cell level.
-
Aprea's Eprenetapopt has not yet reached the primary endpoint of treating TP53 mutant bone marrow growth syndrome
Time of Update: 2021-01-01
company said that patients in the eprenetapoptosine treatment group had a 53 percent higher CR rate than those who used only azat, but that "no statistical difference was achieved." , chief medical officer of Aprea Therapeutics, said: "While we are disappointed with the top line results, we remain confident that eprenetapopt can provide clinical benefits for patients with TP53 mutant malignancies." 。
-
J Clin Oncol: Capivasertib combined with Dositassai and Pernisone to treat metastatic desopathic prostate cancer
Time of Update: 2021-01-01
regardless of the PI3K/AKT/PTEN signal path activation status, cPFS and OS results remain unchanged.
results showed that for mCRPC patients, adding Capivasertib to chemotherapy did not further improve the patient's cPFS, regardless of the status of the PI3K/AKT/PTEN signal path.
-
Br J Cancer: LIMK2-mediated SPOP phosphate degradation promotes the development of descending resistance to prostate cancer
Time of Update: 2021-01-01
PCA tumors that have retained wild-type SPAP can still develop into CRPC, indicating that there are other important regulatory mechanisms to reduce the expression of SPAP.
-
Odivo Patient Assistance Program Updated, Annual Out-of-Pay Ratio Drops By More Than 75%
Time of Update: 2020-12-31
To reduce the initial treatment pressure and reduce the cost of treatment throughout the year, in line with the consistent purpose of the China Cancer Foundation, in order to further improve the access to innovative cancer drugs, the Foundation, with the support of the aid company Shishi Shiguibao, the Foundation has made a number of adjustments to the Odivo Patient Assistance Program.
-
Nat Commun: The immune checkpoint scoring system improves the accuracy of gastric cancer prognosmation assessment
Time of Update: 2020-12-31
In this study, the researchers used the LASSO method (minimum absolute contraction and choice of arithmetic method) to establish an integrated immunometric scoring system (ISSGC) based on six immunosuppressive lipenes (NECTIN2, CEACAM1, HMGB1, SIGLEC6, CD44, and CD155) to improve the accuracy of patient prognostic prediction and to provide alternative treatment strategies for assisted chemotherapy for stomach cancer (GC).
-
Lancet Oncol: The efficacy of the treatment of HER2-positive breast cancer with a single anti-combined pato-pearl single-dose intraseses is comparable to intravenous drug use!
Time of Update: 2020-12-31
This paper reports on the pharmacodynamics, efficacy and safety results of fixed-dose off-the-cortical preparations evaluated in the FeDeriCa study and intravenous patojumal monoantigen and curto-pearl monoantigen as new complementary treatment options for HER2-positive early breast cancer patients.
-
Positive data from the STP705 phase IIa study for the treatment of squamous cell skin cancer
Time of Update: 2020-12-31
, a biopharmaceutical company focused on RNAi drugs, announced today that its leading candidate drug, STP705, has achieved positive results in its Phase IIa clinical study of squamous cell skin cancer.
90% lesions histological removal was achieved in the two optimal dosage ranges.
-
Cell Death Differ: TRIM28-RLIM-MDM2-p53 paths affect the development of lung cancer
Time of Update: 2020-12-31
, the researchers revealed that TRIM28 plays a role in cancer-causing genes in lung cancer, which can reduce p53 expression levels by targeting the ubiganic connective enzymes RLIM and MDM2.
-
Nat Commun: Single-cell analysis reveals different immune conditions for transplanted tumors and primary sarcoma and affects the effectiveness of immunotherapy
Time of Update: 2020-12-31
, however, most preclinical immunotherapy studies focused on transplant tumor models, showing higher cure rates after combined immuno-checkpoint blocking and RT.
tumors and treatments promoted the remodeling of bone marrow cells, and researchers further identified tumor-immersion-related immune cells in transplant tumors and primary tumors, and revealed significant differences in their immune status.
-
J Clin Oncol: A 5-year prognosm of Gfeitinib-assisted treatment of EGFR mutant NSCLC
Time of Update: 2020-12-31
ADJUVANT-CTONG1104 is a randomized Phase III trial that shows that gyfroteni-assisted therapy can significantly improve the disease-free survival (DFS) of patients with non-small cell lung cancer (NSCLC) in stage II-IIIA (N1-N2) surgically removed with EGFR mutations compared to Changchun Ruibin joint cisplatin (VP).
-
CELL: Fudan University's Yu Jia team has revealed a single-celled landscape of early recurrence of liver cancer
Time of Update: 2020-12-31
addition, early recurrence within 2 years of surgery accounts for 70% of relapsed HCC cases, which are rarely treatable and associated with poor survival.
, we still know very little about the molecular mechanisms associated with rapid recurrence of liver cancer after surgery.
-
Nat Commun: Transcription regulator ZFAND3 promotes the invasion of glioblastoma
Time of Update: 2020-12-31
further studies have shown that ZFAND3 plays a key role in nuclear protein complexes, activating gene transcription and regulating the initiation of cell invasion-related genes, including COL6A2, FN1, and NRCAM.
-
Nat Commun: Molecular signs of breast cancer in Asia reveal the specificity of the disease in the population
Time of Update: 2020-12-31
molecular subtype analysis of breast cancer patients in Malaysia In this study, the researchers analyzed the number of genetic mutations, transcriptions and copies in 560 malaysian breast tumor patients, and compared the incidence of breast cancer in Asian and white women.
-
The Lancet Global Health: People with AIDS are six times more likely to develop cervical cancer
Time of Update: 2020-12-31
the world's top 50 countries, the proportion of the population with cervical cancer and HIV in 2018 overall, hiv-infected women have a significant increased risk of cervical cancer.
-
Nat Commun: Multi-histological analysis identified SOX10 as the primary regulatory factor for the glioblastoma RTK I subsype
Time of Update: 2020-12-31
recent large-scale genomics study identified four mRNA expression/DNA methylation subtypes of glioblastoma and their signature genetic lesions: IDH, MES, RTK I, RTK II.
researchers identified 38 subtypes of primary regulatory factors through analysis and further mapped the cell population specific activity of these factors to published single-cell RNA sequencing data.
-
Global esophageal cancer patients in china accounted for half, this treatment is expected to break the multi-year difficulties!
Time of Update: 2020-12-31
Professor Chen Junqiang: The contents include: (1) the prevention of the cause of chest tumors, regular key examinations of high-risk groups, etc., in order to achieve early detection, early diagnosis and early treatment, improve the survival rate of patients and reduce the cost of treatment.
-
The combination therapy of dual-specific antibody KN026 and KN046 was approved by the FDA as an orphan drug for the treatment of stomach cancer and gastroesophageal joint cancer
Time of Update: 2020-12-31
On December 23, Corning Jerry Biopharmaceuticals announced that the company's independently developed dual-specific antibody KN026 (anti-HER2 dual-specific antibody) and KN046 (PD-L1/CTLA-4 dual-specific) The combination therapy was awarded orphan drug (Orphan Drug Designation, ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of HER2-positive or HER2-low expression gastric cancer and gastroesophageal joint cancer (GC/GEJ).
-
"Super minimally invasing"! Specialist digestive endoscopy to cut tumors
Time of Update: 2020-12-31
12-finger intestinal nipples are like unresolted patients wet their eyes after reviewing and Xiao Wu have a similar situation with 63-year-old Lao Xu. Six months ago, he was diagnosed with acute pus bile ductitis, Professor Huang Yonghui's team in its endoscopic stone, the application of self-created technology to nipple sphides and then carried out a "zip-type" stitching, the results of the review recovered well.
